3. Therapy Flow

Patient Journey Analytics · Lines and switches

Ask iZO
DB
Synthetic, de-identified, aggregated data. Illustrative demo.
Step 3 · Therapy Flow

What happens after first-line therapy?

40,000
Patients in view
53.9%
Switch to advanced therapy at line 2
Most switches happen late
19.7%
Brand X switch win share
Line 2 and 3 switches
80.3%
Competitor switch win share
Competitor A, B and C

Lines of therapy, line 1 to line 3

Band width shows number of patients. Advanced-therapy switch points at line 2 and line 3 are highlighted.

Line 1Line 2 (switch point)Line 3 (switch point)L1 Brand X to L2 Brand X: 565 patientsL1 Brand X to L2 Competitor A: 1,259 patientsL1 Brand X to L2 Competitor B: 872 patientsL1 Brand X to L2 Competitor C: 470 patientsL1 Brand X to L2 Conventional: 537 patientsL1 Brand X to L2 No further therapy: 1,931 patientsL1 Competitor A to L2 Brand X: 459 patientsL1 Competitor A to L2 Competitor A: 983 patientsL1 Competitor A to L2 Competitor B: 744 patientsL1 Competitor A to L2 Competitor C: 342 patientsL1 Competitor A to L2 Conventional: 439 patientsL1 Competitor A to L2 No further therapy: 1,508 patientsL1 Competitor B to L2 Brand X: 251 patientsL1 Competitor B to L2 Competitor A: 659 patientsL1 Competitor B to L2 Competitor B: 424 patientsL1 Competitor B to L2 Competitor C: 249 patientsL1 Competitor B to L2 Conventional: 267 patientsL1 Competitor B to L2 No further therapy: 946 patientsL1 Competitor C to L2 Brand X: 161 patientsL1 Competitor C to L2 Competitor A: 328 patientsL1 Competitor C to L2 Competitor B: 239 patientsL1 Competitor C to L2 Competitor C: 111 patientsL1 Competitor C to L2 Conventional: 155 patientsL1 Competitor C to L2 No further therapy: 530 patientsL1 Conventional to L2 Brand X: 3,120 patientsL1 Conventional to L2 Competitor A: 5,157 patientsL1 Conventional to L2 Competitor B: 3,307 patientsL1 Conventional to L2 Competitor C: 1,863 patientsL1 Conventional to L2 Conventional: 3,405 patientsL1 Conventional to L2 No further therapy: 8,719 patientsL2 Brand X to L3 Brand X: 401 patientsL2 Brand X to L3 Competitor A: 938 patientsL2 Brand X to L3 Competitor B: 668 patientsL2 Brand X to L3 Competitor C: 374 patientsL2 Brand X to L3 No further therapy: 2,175 patientsL2 Competitor A to L3 Brand X: 741 patientsL2 Competitor A to L3 Competitor A: 1,621 patientsL2 Competitor A to L3 Competitor B: 1,115 patientsL2 Competitor A to L3 Competitor C: 667 patientsL2 Competitor A to L3 No further therapy: 4,242 patientsL2 Competitor B to L3 Brand X: 478 patientsL2 Competitor B to L3 Competitor A: 1,070 patientsL2 Competitor B to L3 Competitor B: 764 patientsL2 Competitor B to L3 Competitor C: 431 patientsL2 Competitor B to L3 No further therapy: 2,843 patientsL2 Competitor C to L3 Brand X: 268 patientsL2 Competitor C to L3 Competitor A: 626 patientsL2 Competitor C to L3 Competitor B: 421 patientsL2 Competitor C to L3 Competitor C: 239 patientsL2 Competitor C to L3 No further therapy: 1,481 patientsL2 Conventional to L3 Brand X: 409 patientsL2 Conventional to L3 Competitor A: 946 patientsL2 Conventional to L3 Competitor B: 637 patientsL2 Conventional to L3 Competitor C: 382 patientsL2 Conventional to L3 No further therapy: 2,429 patientsBrand X 5,634Competitor A 4,475Competitor B 2,796Competitor C 1,524Conventional 25,571Brand X 4,556Competitor A 8,386Competitor B 5,586Competitor C 3,035Conventional 4,803No further therapy 13,634Brand X 2,297Competitor A 5,201Competitor B 3,605Competitor C 2,093No further therapy 13,170
Brand XCompetitor ACompetitor BCompetitor CConventionalNo further therapy

Who wins the switch?

Share of line 2 and line 3 advanced-therapy switches

Switches happen late, at line 2 and line 3, and a competitor wins more of them. Brand X takes 19.7% of switches while Competitor A alone takes 39.1%.
Getting the switch decision right starts with getting prescriptions filled. Next, see where new Brand X prescriptions drop off.
Where are we losing patients →
Learn and improve.Every data refresh sharpens the next question and the next action.